Menu Search
Equities

Benchmark Holdings PLC

  • Add to watchlist
  • Add to portfolio
  • Add an alert
31B:FRA

Benchmark Holdings PLC

Actions
  • Price (EUR)0.272
  • Today's Change-0.002 / -0.73%
  • Shares traded1.00k
  • 1 Year change-37.90%
  • Beta0.3648
Data delayed at least 15 minutes, as of Jul 18 2025 07:01 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Benchmark Holdings plc is a United Kingdom-based aquaculture biotechnology company. The Company delivers products and solutions that enable aquaculture producers to improve their productivity and sustainability. Its segments include Advanced Nutrition and Health. The Advanced Nutrition segment manufactures and provides technically advanced nutrition and health products to the global aquaculture industry. The Health segment is focused on providing health products to the global aquaculture market. Its animal health solutions include Sea Lice Treatments and Water Purification. Sea lice treatments include Ectosan Vet, Salmosan Vet, and Purisan. It also provides early-stage nutrition for shrimp and marine fish, under the brand INVE Aquaculture. The Company’s advanced nutrition products include A1 DHA SELCO, Artemia AF / BF, ARTEMIA EG / TQ, EASY DRY SELCO, S.PRESSO, ARTEMIA HIGH 5, and others.

  • Revenue in GBP (TTM)50.77m
  • Net income in GBP-48.26m
  • Incorporated2000
  • Employees557.00
  • Location
    Benchmark Holdings PLC4 Park SquareThorncliffe Park, ChapeltownSHEFFIELD S35 2PHUnited KingdomGBR
  • Phone+44 114 240 9939
  • Websitehttps://www.benchmarkplc.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.